ClinicalTrials.gg
CompletedNCT05821712Updated Apr 20, 2023

A New Mouthwash on Reducing Dental Plaque and Helping Prevent Gum Problems

A Phase 3 interventional study of 0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash and 0.057% sodium fluoride Mouthwash in Plaque and Gum Disease, sponsored by Colgate Palmolive. Completed at 1 site in Italy. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-20.

Sponsored by Colgate Palmolive · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Mar 2021, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This 6-month clinical study was designed to investigate clinical efficacy on plaque and gingivitis for the Meridol Base Mouthwash containing 0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride as compared to a Negative Control Mouthwash containing 0.057% sodium fluoride after 3 and 6 months of product use.

02

Conditions studied

  • Plaque
  • Gum Disease

Browse trials for

03

In context

Gingival Diseases

88 studies on the registry are indexed under Gingival Diseases; 23 are open to participants now.

This study's enrollment of 80 is above the median of 46 across 69 interventional studies indexed under Gingival Diseases.

Browse Gingival Diseases studies →

Lead sponsor

Colgate Palmolive is the lead sponsor of 120 studies on the registry; 14 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 2 (6%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects, ages 18-70, inclusive.
  • Availability for the six-month duration of the clinical research study.
  • Good general health.
  • Initial gingivitis index of at least 1.0 as determined by the use of the Loe-Silness Gingival Index.
  • Initial plaque index of at least 1.5 as determined by the use of the Quigley-Hein Plaque Index.
  • Signed Form

Exclusion criteria

Exclusion Criteria:

  • Presence of orthodontic bands.
  • Tumor(s) of the soft or hard tissues of the oral cavity.
  • Advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone).
  • Five or more carious lesions requiring immediate restorative treatment.
  • Antibiotic use any time during the one-month period prior to entry into the study.
  • Participation in any other clinical study or test panel within the one month prior to entry into the study.
  • Dental prophylaxis during the past two weeks prior to baseline examinations.
  • History of allergies to oral care/personal care consumer products or their ingredients.
  • On any prescription medicines that might interfere with the study outcome.
  • An existing medical condition that prohibits eating or drinking for periods up to 4 hours.
  • History of alcohol or drug abuse.
  • Self-reported pregnant or lactating subjects
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash

    mouthwash

    Drug: 0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash

  • Active comparator
    0.057% sodium fluoride Mouthwash

    mouthwash

    Drug: 0.057% sodium fluoride Mouthwash

Interventions

06

What researchers measure

Primary outcomes

  1. Gingival inflammation

    Loe-Silness Gingival Index

    Time frame: baseline

  2. Gingival inflammation

    Loe-Silness Gingival Index

    Time frame: 3 months

  3. Gingival inflammation

    Loe-Silness Gingival Index

    Time frame: 6 months

07

Study locations

1 site
  • Clinica Odontoiatrica Montesani
    Roma, Rome 00187, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Sep 2021, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2023
First posted
Apr 20, 2023
StartActual
Mar 8, 2021
Primary completionActual
Sep 24, 2021
CompletionActual
Sep 24, 2021
Last update
Apr 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05821712
Lead sponsor
Colgate Palmolive
Responsible party
Sponsor
First posted
Apr 20, 2023
Start date
Mar 8, 2021
Primary completion
Sep 24, 2021
Completion
Sep 24, 2021
Last update
Apr 20, 2023

Study contacts

Luigi Montesani, MD, DDS
principal investigator · Clinica Odontoiatrica Montesani

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zinc lactate

Start the discussion